IBDEI0JY ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,9772,1,4,0)
 ;;=4^435.9
 ;;^UTILITY(U,$J,358.3,9772,1,5,0)
 ;;=5^Transient Ischemic Attack
 ;;^UTILITY(U,$J,358.3,9772,2)
 ;;=^21635
 ;;^UTILITY(U,$J,358.3,9773,0)
 ;;=354.2^^67^667^76
 ;;^UTILITY(U,$J,358.3,9773,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9773,1,4,0)
 ;;=4^354.2
 ;;^UTILITY(U,$J,358.3,9773,1,5,0)
 ;;=5^Ulnar Nerve Entrapment
 ;;^UTILITY(U,$J,358.3,9773,2)
 ;;=^268506
 ;;^UTILITY(U,$J,358.3,9774,0)
 ;;=729.1^^67^667^17
 ;;^UTILITY(U,$J,358.3,9774,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9774,1,4,0)
 ;;=4^729.1
 ;;^UTILITY(U,$J,358.3,9774,1,5,0)
 ;;=5^Fibromyalgia
 ;;^UTILITY(U,$J,358.3,9774,2)
 ;;=Fibromyalgia^80160
 ;;^UTILITY(U,$J,358.3,9775,0)
 ;;=438.20^^67^667^6
 ;;^UTILITY(U,$J,358.3,9775,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9775,1,4,0)
 ;;=4^438.20
 ;;^UTILITY(U,$J,358.3,9775,1,5,0)
 ;;=5^CVA w/Hemiplegia (late effect)
 ;;^UTILITY(U,$J,358.3,9775,2)
 ;;=CVA w/Hemiplegia^317910
 ;;^UTILITY(U,$J,358.3,9776,0)
 ;;=438.12^^67^667^5
 ;;^UTILITY(U,$J,358.3,9776,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9776,1,4,0)
 ;;=4^438.12
 ;;^UTILITY(U,$J,358.3,9776,1,5,0)
 ;;=5^CVA w/Dysphasia (late effect)
 ;;^UTILITY(U,$J,358.3,9776,2)
 ;;=Stroke w/Dysphasia^317908
 ;;^UTILITY(U,$J,358.3,9777,0)
 ;;=356.8^^67^667^63
 ;;^UTILITY(U,$J,358.3,9777,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9777,1,4,0)
 ;;=4^356.8
 ;;^UTILITY(U,$J,358.3,9777,1,5,0)
 ;;=5^Peripheral Neuropathy, Idiopathic
 ;;^UTILITY(U,$J,358.3,9777,2)
 ;;=Peripheral Neuropathy, Idio^268525
 ;;^UTILITY(U,$J,358.3,9778,0)
 ;;=337.20^^67^667^68
 ;;^UTILITY(U,$J,358.3,9778,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9778,1,4,0)
 ;;=4^337.20
 ;;^UTILITY(U,$J,358.3,9778,1,5,0)
 ;;=5^Reflexive Sympathetic Dystrophy
 ;;^UTILITY(U,$J,358.3,9778,2)
 ;;=Reflexive Sympathetic Dystrophy^295799
 ;;^UTILITY(U,$J,358.3,9779,0)
 ;;=294.8^^67^667^14
 ;;^UTILITY(U,$J,358.3,9779,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9779,1,4,0)
 ;;=4^294.8
 ;;^UTILITY(U,$J,358.3,9779,1,5,0)
 ;;=5^Dementia, Other
 ;;^UTILITY(U,$J,358.3,9779,2)
 ;;=^268044
 ;;^UTILITY(U,$J,358.3,9780,0)
 ;;=438.6^^67^667^4
 ;;^UTILITY(U,$J,358.3,9780,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9780,1,4,0)
 ;;=4^438.6
 ;;^UTILITY(U,$J,358.3,9780,1,5,0)
 ;;=5^CVA w/Dysesthesia (late effect)
 ;;^UTILITY(U,$J,358.3,9780,2)
 ;;=CVA w/Dysesthesia (late effect)^328503
 ;;^UTILITY(U,$J,358.3,9781,0)
 ;;=438.7^^67^667^7
 ;;^UTILITY(U,$J,358.3,9781,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9781,1,4,0)
 ;;=4^438.7
 ;;^UTILITY(U,$J,358.3,9781,1,5,0)
 ;;=5^CVA w/Vision Changes (late effect)
 ;;^UTILITY(U,$J,358.3,9781,2)
 ;;=CVA w/Vision Changes (late effect)^328504
 ;;^UTILITY(U,$J,358.3,9782,0)
 ;;=438.84^^67^667^3
 ;;^UTILITY(U,$J,358.3,9782,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9782,1,4,0)
 ;;=4^438.84
 ;;^UTILITY(U,$J,358.3,9782,1,5,0)
 ;;=5^CVA w/Ataxia (late effect)
 ;;^UTILITY(U,$J,358.3,9782,2)
 ;;=CVA w/Ataxia (late effect)^328507
 ;;^UTILITY(U,$J,358.3,9783,0)
 ;;=434.91^^67^667^8
 ;;^UTILITY(U,$J,358.3,9783,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9783,1,4,0)
 ;;=4^434.91
 ;;^UTILITY(U,$J,358.3,9783,1,5,0)
 ;;=5^CVA, Acute Onset
 ;;^UTILITY(U,$J,358.3,9783,2)
 ;;=^295738
 ;;^UTILITY(U,$J,358.3,9784,0)
 ;;=333.94^^67^667^69
 ;;^UTILITY(U,$J,358.3,9784,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9784,1,4,0)
 ;;=4^333.94
 ;;^UTILITY(U,$J,358.3,9784,1,5,0)
 ;;=5^Restless Leg Syndrome
 ;;^UTILITY(U,$J,358.3,9784,2)
 ;;=^105368
 ;;^UTILITY(U,$J,358.3,9785,0)
 ;;=345.90^^67^667^71
 ;;^UTILITY(U,$J,358.3,9785,1,0)
 ;;=^358.31IA^5^2
